The global stem cell market size was estimated at USD 8.65 billion in 2018 and is anticipated to expand at a CAGR of 8.8% over the forecast period. Despite being a controversial concept, stem cells have gained significant attention from multidisciplinary community of scientists. Factors that have influenced the growth of this market are huge success of regenerative medicine as well as exponential growth in ongoing research.
The technology has gained importance over the years as it is directly associated with regenerative medicine and treatment of diseased organs and damaged tissues. Research activities targeted at development of biomaterial systems that are polymeric in nature have witnessed a rise in recent years. These systems function as a niche aiding in improvement of survival of stem cell.
This is set to open new avenues for the application of advanced technologies in wound healing therapy, propelling the market growth. Revolutionary innovations aimed at increasing the supply of Induced Pluripotent Stem Cells (iPSCs) and biomaterial development used in stem cell transplantation. Such advancements enable researchers to generate pluripotent stem cells from adult somatic cells which further helps preserve genetic information within these cells.
Increased research activity has revolutionized the “clinical trial in a dish” in areas that are dominated by the personalized medicine approach. In addition, prevalence of disorders treatable with the help of this technology is expected to continue in near future. According to the WideCells Group, between 2005 and 2013, there has been a 300% increase in the number of diseases that can be treated by stem cells.
Research on exploiting full potential of stem cells proves to be the key driving factor for the growth of the market. Companies are also funding research activities focused exclusively on application in regenerative medicine. Understanding the role of stem cells, funding bodies continue to increase their investment for accelerating research. However, ethical concerns coupled with public perception in context to stem cell research at different phases of research is anticipated to impede the implementation of stem cell therapy to a certain extent.
Adult stem cell segment held the largest market share of USD 7.38 billion in 2018 and is estimated to continue leading during the forecast period. This is attributed to the low risks of contamination linked to sub-culturing, minimal requirement of production labor, and compatibility with human body.
The iPSCs segment is anticipated to witness the fastest CAGR during the forecast period as iPSCs provide a window into human development owing to the technological breakthroughs. Proliferating research activities related to stem cell use in drug screening and organoid generation have emerged as key driving factors of this segment.
Regenerative medicine is observed to hold the potential for devising early-intervention treatments to cure degenerative diseases and traumatic injury. Furthermore, availability of regenerative medicine across a wide range of clinical areas is driving the segment growth. Neurology held the largest market share in terms of revenue in regenerative medicine attributed to the increasing number of significant FDA approved products. However, strong pipeline portfolio for cancer therapies is anticipated to boost growth in oncology regenerative medicine.
Stem cells are recognized to create new opportunities for pharmaceutical companies by advancing the identification of lead candidates and enabling firms to develop novel drugs. Moreover, research has advanced single-cell analysis which helps study drug effects on cell differentiation. In addition, growing reliance of drug developing entities on cellular systems is anticipated to help this segment in gaining ground in near future.
Cell acquisition technology is the basic predominant step which has resulted in the dominance of this segment. It is expected to maintain this position throughout the forecast period, owing to rising awareness regarding the significance of stem cells. Bone marrow is the most used technology for cell acquisition owing to the relatively faster production of new cells from bone marrow. Further, cells that originate from bone marrow are more concentrated as compared to other origin sites.
Cell production technology accounted for the significant share owing to the ongoing technological advancements, aimed at fulfilling the growing need from various clinical applications. On the basis of steps, the technology is segregated into therapeutic cloning, in-vitro fertilization, cell culture, and isolation. Rising number of organ replacement procedures along with the demand for therapeutic has spurred the segment growth. For instance, pancreas transplants accounted for approximately 2,300 transplant surgeries in 2016 across the globe.
Autologous stem cell therapy emerged as the dominant segment in terms of revenue generation in 2018, attributed to large scale consumption of these products due to associative high compatibility. In addition, expanding systematic reviews and meta-analysis studies on studying the effectiveness of autologous stem cell therapy on treatment of lower limb disorders will further offer momentum to the market. Although the marketplace is unregulated and is scrutinized by several government bodies, several companies engage in development of autologous products for patients with sports injuries. This factor is anticipated to prove critical for the segment growth in the forthcoming years.
Asia Pacific is projected to register the fastest CAGR during the forecast period. Emerging countries such as Japan, Australia, and Singapore are largely investing in the R&D projects, which is set to drive regional growth. Countries from Asia Pacific region are expected to be at the forefront of rapidly evolving stem cell industry. Factors like favorable regulatory policies along with commercialization opportunities supplement the regional expansion. Regulatory amendments pertaining to regenerative medicine in Japan have attracted international manufacturers to invest in the Japanese market.
North America is anticipated to continue holding the leading market share over the forecast period, owing to the efforts from private and government sectors working towards establishment of well-defined business models in U.S. and Canada.
Some of the key market players include Celgene Corporation; STEMCELL Technologies Inc.; Osiris Therapeutics Inc.; BIOTIME, INC.; Advanced Cell Technology Inc.; Cytori Therapeutics; Cynata; Human Longevity Inc.; Mesoblast; and Promethera Biosciences.Companies are opting for multidisciplinary business expansion and multi-sector collaboration to ensure continuous supply of high quality pluripotent and differentiated cells. This is set to intensify the competition, driving the constant need to launch novel products.
Base year for estimation
Actual estimates/Historical data
2014 - 2017
2019 - 2025
Revenue in USD Billion and CAGR from 2019 to 2025
North America, Europe, Asia Pacific, Latin America, Middle East & Africa
U.S., Canada, Germany, U.K., China, Japan, Brazil, South Africa
Revenue forecast, company share, competitive landscape, growth factors and trends
15% free customization scope (equivalent to 5 analyst working days)
If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of customization
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the global stem cell market report on the basis of product, application, technology, therapy, and region:
Product Outlook (Revenue, USD Billion, 2014 - 2025)
Adult Stem Cells
Induced Pluripotent Stem Cells
Very Small Embryonic Like Stem Cells
Application Outlook (Revenue, USD Billion, 2014 - 2025)
Cardiovascular and Myocardial Infraction
Drug Discovery and Development
Technology Outlook (Revenue, USD Billion, 2014 - 2025)
Bone Marrow Harvest
Umbilical Blood Cord
Expansion and Sub-Culture
Therapy Outlook (Revenue, USD Billion, 2014 - 2025)
Autologous Stem Cell Therapy
Allogeneic Stem Cell Therapy
Regional Outlook (Revenue, USD Billion, 2014 - 2025)
Middle East & Africa
Avail customized purchase options to meet your exact research needs:
Get your queries resolved from an industry expert.
Design an exclusive study to serve your research needs.
A testimonial for service in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.
"The quality of research they have done for us has been excellent..."